India
· Delayed Price · Currency is INR Concord Biotech Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 173.97 billion. The enterprise value is 171.16 billion.
| Market Cap | 173.97B |
| Enterprise Value | 171.16B |
Important Dates
The next estimated earnings date is Friday, May 23, 2025.
| Earnings Date | May 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Concord Biotech has 104.62 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 104.62M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 62.50% |
| Owned by Institutions (%) | 15.66% |
| Float | 24.92M |
Valuation Ratios
The trailing PE ratio is 53.31 and the forward PE ratio is 41.11. Concord Biotech's PEG ratio is 1.64.
| PE Ratio | 53.31 |
| Forward PE | 41.11 |
| PS Ratio | 15.97 |
| PB Ratio | 10.94 |
| P/TBV Ratio | 10.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.64 |
Enterprise Valuation
| EV / Earnings | 52.46 |
| EV / Sales | 15.71 |
| EV / EBITDA | 37.50 |
| EV / EBIT | 42.41 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | n/a |
| Interest Coverage | 452.29 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 17.06% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 7.91M |
| Profits Per Employee | 2.37M |
| Employee Count | 1,377 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.94% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +8.94% |
| 50-Day Moving Average | 1,858.60 |
| 200-Day Moving Average | 1,878.32 |
| Relative Strength Index (RSI) | 46.05 |
| Average Volume (20 Days) | 265,501 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 10.89 billion and earned 3.26 billion in profits. Earnings per share was 31.19.
| Revenue | 10.89B |
| Gross Profit | 8.05B |
| Operating Income | 4.06B |
| Pretax Income | 4.40B |
| Net Income | 3.26B |
| EBITDA | 4.57B |
| EBIT | 4.06B |
| Earnings Per Share (EPS) | 31.19 |
Balance Sheet
The company has 2.84 billion in cash and 34.24 million in debt, giving a net cash position of 2.80 billion or 26.79 per share.
| Cash & Cash Equivalents | 2.84B |
| Total Debt | 34.24M |
| Net Cash | 2.80B |
| Net Cash Per Share | 26.79 |
| Equity (Book Value) | 15.90B |
| Book Value Per Share | 151.99 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 73.90%, with operating and profit margins of 37.23% and 29.96%.
| Gross Margin | 73.90% |
| Operating Margin | 37.23% |
| Pretax Margin | 40.37% |
| Profit Margin | 29.96% |
| EBITDA Margin | 41.93% |
| EBIT Margin | 37.23% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 8.75, which amounts to a dividend yield of 0.52%.
| Dividend Per Share | 8.75 |
| Dividend Yield | 0.52% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.02% |
| Shareholder Yield | 0.51% |
| Earnings Yield | 1.88% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |